Physician profile
William E Stricker
NPI 1902095979
$3,530.01
in general payments reported to CMS, 2019-2025
24 companies · $803 in 2025
The $803 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $220 · 2021: $321 · 2022: $475 · 2023: $591 · 2024: $925 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $947.43 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $393.13 | 2022-2025 | Dupixent |
| Optinose US, INC. | $376.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $342.60 | 2019-2025 | Nucala |
| Genzyme Corporation | $266.74 | 2020-2025 | |
| Grifols USA, LLC | $249.91 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $201.79 | 2021-2025 | |
| Genentech USA, INC. | $174.19 | 2024-2025 | Xolair |
| Horizon Therapeutics Plc | $137.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.17 | 2021-2025 | Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $65.22 | 2025 | Neffy |
| Octapharma USA, INC. | $55.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.04 | 2021 | |
| Viatris Specialty LLC | $20.25 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $19.97 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $19.60 | 2021 | |
| Galderma Laboratories, L.P. | $18.03 | 2025 | Nemluvio |
| Adma Biomanufacturing LLC | $17.95 | 2022 | |
| Verona Pharma, INC. | $17.57 | 2025 | Ohtuvayre |
| Pfizer INC. | $16.15 | 2019 | |
| Uswm, LLC | $16.00 | 2021 | |
| Pharming Healthcare, INC. | $15.44 | 2021 | |
| Abbvie INC. | $14.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stricker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.